Evidence map›Paper›PMID 28453706›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.

N Romero-Laorden, E Piñeiro-Yañez, A Gutierrez-Pecharroman, M I Pacheco, E Calvo, F Al-Shahrour, E Castro, D Olmos

Open access · bronzeAbstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Review
  5. Acquiring evidence for precision prostate cancer care.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

N Romero-LaordenProstate Cancer Unit, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid.
E Piñeiro-YañezBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid.
A Gutierrez-PecharromanProstate Cancer Unit, Spanish National Cancer Research Centre.
M I PachecoProstate Cancer Unit, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid.
E CalvoSTART Madrid, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid.
F Al-ShahrourBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid.
E CastroProstate Cancer Unit, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid.
D OlmosProstate Cancer Unit, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid.
Spanish National Cancer Research Centre · ESSouth Texas Accelerated Research Therapeutics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genes, BRCA2Loss of HeterozygosityAgedBenzimidazolesBRCA2 ProteinGerm-Line MutationHumansMalePoly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantBenzimidazolesBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase Inhibitorsveliparib

Identifiers

PMID28453706
OpenAlexW2591749037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.